MX2021006856A - Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares. - Google Patents

Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares.

Info

Publication number
MX2021006856A
MX2021006856A MX2021006856A MX2021006856A MX2021006856A MX 2021006856 A MX2021006856 A MX 2021006856A MX 2021006856 A MX2021006856 A MX 2021006856A MX 2021006856 A MX2021006856 A MX 2021006856A MX 2021006856 A MX2021006856 A MX 2021006856A
Authority
MX
Mexico
Prior art keywords
bile acid
treatment
methods
diseases
disorders
Prior art date
Application number
MX2021006856A
Other languages
English (en)
Inventor
Lei Ling
Jian Luo
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of MX2021006856A publication Critical patent/MX2021006856A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)

Abstract

La invención se refiere a las variantes y fusiones del factor de crecimiento de los fibroblastos 19 (FGF19), a las variantes y fusiones del factor de crecimiento de los fibroblastos 21 (FGF21), las fusiones de FGF19 y/o FGF21, y las variantes o fusiones de las proteínas FGF19 y/o FGF21, y las secuencias peptídicas (y peptidomiméticos), que tienen una o más actividades, como puede ser la actividad moduladora de la homeostasis de los ácidos biliares, y a los métodos para, y usos en, el tratamiento de los trastornos causados por los ácidos biliares y otros trastornos.
MX2021006856A 2012-12-27 2015-06-22 Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares. MX2021006856A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261746499P 2012-12-27 2012-12-27
US201361779604P 2013-03-13 2013-03-13
US201361887129P 2013-10-04 2013-10-04

Publications (1)

Publication Number Publication Date
MX2021006856A true MX2021006856A (es) 2021-07-02

Family

ID=51022055

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008226A MX2015008226A (es) 2012-12-27 2013-12-26 Metodos para modular la homeostasis de los acidos biliares, y tratamiento de trastornos y enfermedades causadas por los acidos biliares.
MX2021006856A MX2021006856A (es) 2012-12-27 2015-06-22 Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015008226A MX2015008226A (es) 2012-12-27 2013-12-26 Metodos para modular la homeostasis de los acidos biliares, y tratamiento de trastornos y enfermedades causadas por los acidos biliares.

Country Status (18)

Country Link
US (6) US9925242B2 (es)
EP (2) EP4083221A1 (es)
JP (1) JP6403685B2 (es)
KR (3) KR20150104579A (es)
CN (2) CN108888757A (es)
AU (1) AU2013370404B2 (es)
CA (1) CA2895517C (es)
DK (1) DK2938740T3 (es)
ES (1) ES2915851T3 (es)
HK (1) HK1215283A1 (es)
IL (2) IL292303A (es)
MX (2) MX2015008226A (es)
NZ (1) NZ630469A (es)
PL (1) PL2938740T3 (es)
RU (1) RU2675514C2 (es)
SG (2) SG10202100667SA (es)
WO (1) WO2014105939A1 (es)
ZA (1) ZA201504484B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
KR102077721B1 (ko) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
BR112016009099A2 (pt) 2013-10-28 2017-09-19 Ngm Biopharmaceuticals Inc Método para determinar se um indivíduo de teste tendo um distúrbio metabólico é um candidato para o tratamento com uma variante de fgf19, método para determinar se uma variante de fgf19 é um candidato para tratar um indivíduo de teste, uso de uma variante fgf19, modelo para determinar se uma variante de fgf19 é um candidato para prevenir uma doença
MY191944A (en) 2014-01-24 2022-07-20 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
EP3125921B1 (en) 2014-03-11 2020-07-08 Novartis AG Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN107108711B (zh) * 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
PT3236991T (pt) * 2014-12-23 2019-09-06 Novo Nordisk As Derivados de fgf21 e usos dos mesmos
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CA3000697A1 (en) * 2015-10-01 2017-04-06 Amgen Inc. Treatment of bile acid disorders
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CN105424941B (zh) * 2015-11-09 2018-04-10 湖南莱拓福生物科技有限公司 Akr1b10蛋白和用于肝硬化诊断的试剂盒
US11633454B2 (en) 2016-05-30 2023-04-25 Shanghai Hep Pharmaceutical Co., Ltd. Compositions and methods for treating metabolic diseases
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
WO2018044778A1 (en) * 2016-08-29 2018-03-08 NGM Biopharmaceuticals, Inc Methods for treatment of bile acid-related disorders
US11229643B2 (en) 2016-11-02 2022-01-25 Novartis Ag Combinations of FGFR4 inhibitors and bile acid sequestrants
WO2018195390A1 (en) * 2017-04-21 2018-10-25 Ngm Biopharmaceuticals, Inc. Methods of treating gastrointestinal motility -related disorders using variants and fusions of fgf19/fgf21 polypeptides
JOP20190276A1 (ar) * 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
EP3955954A4 (en) * 2019-04-17 2023-05-17 NGM Biopharmaceuticals, Inc. MULTIPLE THERAPY FOR THE MODULATION OF BILE ACID HOMEOSTASIS AND THE TREATMENT OF BILE ACID DISORDERS AND DISEASES
WO2020231909A1 (en) * 2019-05-11 2020-11-19 Steven Hoffman Compositions and methods for treating bile acid associated diseases
CN111420030B (zh) * 2020-05-12 2021-01-29 江南大学 Fgf21在制备用于治疗结直肠癌药物中的应用
CN113735959B (zh) * 2021-03-12 2023-07-04 江南大学 一种治疗nash的fgf类似物

Family Cites Families (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
JPH04503306A (ja) 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション 単純ヘルペスウイルス１型発現ベクター
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AU3972893A (en) 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
WO1994029442A2 (en) 1993-06-14 1994-12-22 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
EP0728202A4 (en) 1993-11-12 1997-04-23 Univ Case Western Reserve EPISOMIC EXPRESSION VECTOR FOR HUMAN GENE THERAPY
CA2117668C (en) 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5695977A (en) 1995-08-31 1997-12-09 Genetic Information Research Institute Site directed recombination
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP4162267B2 (ja) 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20060246540A1 (en) 1997-08-26 2006-11-02 Ashkenazi Avi J Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020012961A1 (en) 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
US20030113718A1 (en) 1997-09-17 2003-06-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6806352B2 (en) 1997-09-17 2004-10-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE447583T1 (de) 1997-09-17 2009-11-15 Genentech Inc Polypeptide und dafür kodierende nukleinsäure
US20030077654A1 (en) 1997-09-17 2003-04-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050026832A1 (en) 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20040126852A1 (en) 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US20020155543A1 (en) 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20030185846A1 (en) 1998-09-16 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000060085A1 (en) 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US7390879B2 (en) 1999-06-15 2008-06-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7129072B1 (en) 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU7368100A (en) 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
US6797695B1 (en) 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
PT1232264E (pt) 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Gene fgf-21 humano e produtos da expressão do gene
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
WO2001049849A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
AU2759201A (en) 2000-01-05 2001-07-16 Zymogenetics Inc. Novel fgf homolog zfgf12
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
US20010044525A1 (en) 2000-01-05 2001-11-22 Conklin Darrell C. Novel FGF Homolog zFGF12
WO2001061007A2 (en) 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
US20060160181A1 (en) 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
WO2001066595A2 (en) 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
US20030105302A1 (en) 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
WO2001072957A2 (en) 2000-03-31 2001-10-04 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
US20030065140A1 (en) 2000-04-03 2003-04-03 Vernet Corine A.M. Novel proteins and nucleic acids encoding same
JP2002112772A (ja) 2000-07-10 2002-04-16 Takeda Chem Ind Ltd 新規ポリペプチドおよびそのｄｎａ
ATE461213T1 (de) 2000-07-19 2010-04-15 Advanced Res & Tech Inst Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
EP1309685A2 (en) 2000-07-20 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7115415B2 (en) 2000-09-15 2006-10-03 Genentech, Inc. PRO9821 nucleic acids
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
AU2002230531A1 (en) 2000-11-22 2002-06-03 Bayer Corporation Use of fgf-19 for inhibiting angiogenesis
US20020151496A1 (en) 2000-12-08 2002-10-17 Bringmann Peter W. Novel fibroblast growth factors
DE10100588A1 (de) 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
DE10100587C1 (de) 2001-01-09 2002-11-21 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
US20030119112A1 (en) 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003225903A1 (en) 2002-03-21 2003-10-08 Curagen Corporation Methods of using farnesoid x receptor (fxr) agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
AU2003243400B2 (en) 2002-06-07 2009-10-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
EP1545584A4 (en) 2002-09-18 2007-04-04 Lilly Co Eli METHOD FOR REDUCING MORBIDITY AND MORTALITY OF CRITICAL SICK PATIENTS
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
PT1641483E (pt) 2003-06-12 2008-04-29 Lilly Co Eli Proteínas de fusão
PL1648998T3 (pl) 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
CN1890371A (zh) 2003-12-10 2007-01-03 伊莱利利公司 成纤维细胞生长因子的21突变蛋白
EP1725589A1 (en) 2004-03-11 2006-11-29 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
DK1751184T3 (da) 2004-05-13 2009-11-23 Lilly Co Eli FGF-21 fusionsproteiner
KR20120133403A (ko) 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
JP2006016323A (ja) 2004-06-30 2006-01-19 Hiroshima Industrial Promotion Organization 生理活性バイオマテリアル
DK1789442T3 (da) 2004-09-02 2009-11-16 Lilly Co Eli Muteiner af fibroblastvækstfaktor 21
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
ZA200704338B (en) 2004-10-29 2009-03-25 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
US20060134663A1 (en) 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same
WO2006065582A2 (en) 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
EP1929043A4 (en) 2005-08-24 2009-10-28 Genizon Biosciences Inc GENETIC CARD OF HUMAN GENES ASSOCIATED WITH CROHN'S DISEASE
EP1987055A1 (en) 2006-02-10 2008-11-05 Dermagen AB Novel antimicrobial peptides and use thereof
WO2007130673A2 (en) 2006-05-05 2007-11-15 Beth Israel Deaconess Medical Center Methods for the diagnosis and treatment of female infertility using molecular markers
US8168169B2 (en) 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
CN101563597A (zh) 2006-09-01 2009-10-21 美国菌种保藏中心 用于诊断和治疗2型糖尿病的组合物和方法
AU2007315211B2 (en) 2006-11-03 2013-01-17 U3 Pharma Gmbh FGFR4 antibodies
EP2457997B1 (en) 2007-01-03 2016-08-31 NeoStem Oncology, LLC Stem cell growth media and methods of making and using same
SI2068909T1 (sl) * 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
AU2008232937B2 (en) 2007-03-30 2012-09-27 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
LT2550972T (lt) 2007-04-02 2018-05-10 Genentech, Inc. Kloto-beta agonistinis antikūnas, skirtas cukrinio diabeto arba atsparumo insulinui gydymui
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
WO2009076478A2 (en) 2007-12-10 2009-06-18 The Johns Hopkins University Hypomethylated genes in cancer
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
US20090226459A1 (en) 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
NZ602702A (en) 2008-03-19 2014-03-28 Ambrx Inc Modified fgf-21 polypeptides and their uses
WO2009117622A2 (en) 2008-03-19 2009-09-24 Ambrx, Inc. Modified fgf-23 polypeptides and their uses
WO2009116861A2 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN101591653B (zh) 2008-05-27 2013-07-31 中国人民解放军军事医学科学院野战输血研究所 低表达cyp7a1的肝细胞及其构建方法
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
US8363365B2 (en) 2008-06-17 2013-01-29 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
EP2300825A4 (en) 2008-06-18 2012-04-25 Abbott Lab P / GF 1 COMPARATIVE DIAGNOSTIC PROCEDURES AND PRODUCTS
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010006214A1 (en) 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
US20110268794A1 (en) 2009-01-09 2011-11-03 Camilleri Michael L Methods and materials for delivering bile acids
WO2010080976A1 (en) 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
US20100274362A1 (en) 2009-01-15 2010-10-28 Avner Yayon Cartilage particle tissue mixtures optionally combined with a cancellous construct
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
PE20160718A1 (es) 2009-05-05 2016-08-03 Amgen Inc Polipeptidos mutantes fgf21
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US10241093B2 (en) 2009-05-28 2019-03-26 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
US20120076729A1 (en) 2009-06-04 2012-03-29 Novartis Ag Methods of treating cancers
EP2440235A1 (en) 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
MX2011013903A (es) 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN101993496B (zh) * 2009-08-20 2013-06-05 重庆富进生物医药有限公司 双重调节血糖血脂融合蛋白及其制法和用途
CA2777717C (en) * 2009-10-15 2021-05-25 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011084808A2 (en) 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
WO2011130729A2 (en) 2010-04-16 2011-10-20 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
EP2595647A1 (en) 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
CN103221039A (zh) 2010-09-09 2013-07-24 三叶草私人有限公司 血管生成抑制剂的气道给药
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
CN102464712A (zh) 2010-11-11 2012-05-23 重庆富进生物医药有限公司 缺失型人成纤维细胞生长因子21变异体及其偶联物
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
JP5613547B2 (ja) 2010-12-14 2014-10-22 株式会社スクウェア・エニックス タスクベースの並列プログラミング言語
AU2011348202A1 (en) 2010-12-22 2013-07-04 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides
JP5850435B2 (ja) 2010-12-24 2016-02-03 国立研究開発法人産業技術総合研究所 ヒトｆｇｆ１９活性の正確で高感度な測定方法ならびにヒトｆｇｆ１９活性の制御剤
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
MX2013013044A (es) 2011-05-10 2014-02-20 Amgen Inc METODO PARA IDENTIFICAR COMPUESTOS QUE ESPECIFICAMENTE MODULAN LA INTERACCION DE FGFR1 Y ß-KLOTHO.
SG194917A1 (en) 2011-05-16 2013-12-30 Genentech Inc Fgfr1 agonists and methods of use
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2012170704A2 (en) 2011-06-08 2012-12-13 Denovo Biomarkers Inc. Methods and compositions of predicting activity of retinoid x receptor modulator
EP2723391B1 (en) 2011-06-24 2018-06-13 University of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
KR102077721B1 (ko) * 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
MX2014002260A (es) 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
CN103127503B (zh) 2011-11-23 2017-11-10 上海医学生命科学研究中心有限公司 拮抗和/或阻断IL‑6/IL‑6R/gp130信号通路在抗肝癌治疗中的用途
CA2862424A1 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
WO2013131091A1 (en) 2012-03-02 2013-09-06 New York University Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
JP2013194049A (ja) 2012-03-23 2013-09-30 Kazuo Todokoro ヒト造血幹細胞を増幅させるための組成物及び方法
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
US9771567B2 (en) 2012-04-16 2017-09-26 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho variant polypeptides
US20150141335A1 (en) 2012-05-15 2015-05-21 Eli Lilly And Company Therapeutic uses of fibroblast growth factor 21 proteins
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
EP2859014B1 (en) 2012-06-11 2017-04-26 Eli Lilly and Company Fibroblast growth factor 21 variants
KR102163776B1 (ko) 2012-07-11 2020-10-12 블루프린트 메디신즈 코포레이션 섬유아세포 성장인자 수용체의 저해제
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
PE20150648A1 (es) 2012-09-07 2015-05-25 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2014152089A1 (en) 2013-03-14 2014-09-25 Georgetown University Compositions and treatments of metabolic disorders using fgf binding protein 3
US9789160B2 (en) 2013-03-14 2017-10-17 Georgetown University Treatments for lowering glucose levels using FGF binding protein 3
WO2014152090A1 (en) 2013-03-14 2014-09-25 Georgetown University Compositions and treatments of metabolic disorders using fgf binding protein 3 and fgf 19
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
US9835631B2 (en) 2013-04-15 2017-12-05 Nordic Bioscience A/S Combined biomarker measurement of fibrosis
SG11201603134XA (en) 2013-10-21 2016-05-30 Salk Inst For Biological Studi Mutated fibroblast growth factor (fgf) 1 and methods of use
BR112016009099A2 (pt) 2013-10-28 2017-09-19 Ngm Biopharmaceuticals Inc Método para determinar se um indivíduo de teste tendo um distúrbio metabólico é um candidato para o tratamento com uma variante de fgf19, método para determinar se uma variante de fgf19 é um candidato para tratar um indivíduo de teste, uso de uma variante fgf19, modelo para determinar se uma variante de fgf19 é um candidato para prevenir uma doença
MY191944A (en) 2014-01-24 2022-07-20 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
US20170173114A1 (en) 2014-05-07 2017-06-22 Joslin Diabetes Center, Inc. Methods and compositions for induction of ucp1 expression
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016048995A2 (en) 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf19 truncations and mutants and uses thereof
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
EP3108893A1 (en) 2015-06-25 2016-12-28 Universite Claude Bernard - Lyon 1 Novel therapeutic use of fgf19
AU2016326689A1 (en) 2015-09-24 2018-03-22 Genentech, Inc. Methods for the treatment of epilepsy
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
WO2018044778A1 (en) 2016-08-29 2018-03-08 NGM Biopharmaceuticals, Inc Methods for treatment of bile acid-related disorders
KR102340750B1 (ko) 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제
CN108619490A (zh) 2017-03-22 2018-10-09 天士力医药集团股份有限公司 一种长效化突变的人源成纤维生长因子的新用途
WO2018195390A1 (en) 2017-04-21 2018-10-25 Ngm Biopharmaceuticals, Inc. Methods of treating gastrointestinal motility -related disorders using variants and fusions of fgf19/fgf21 polypeptides
JP7316946B2 (ja) 2017-07-06 2023-07-28 イエール ユニバーシティ 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法
WO2020176703A1 (en) 2019-02-28 2020-09-03 Ngm Biopharmaceuticals, Inc. Non-invasive biomarkers for use in the treatment of non-alcoholic steatohepatitis and other bile acid-related disorders
EP3955954A4 (en) 2019-04-17 2023-05-17 NGM Biopharmaceuticals, Inc. MULTIPLE THERAPY FOR THE MODULATION OF BILE ACID HOMEOSTASIS AND THE TREATMENT OF BILE ACID DISORDERS AND DISEASES

Also Published As

Publication number Publication date
HK1215283A1 (zh) 2016-08-19
JP6403685B2 (ja) 2018-10-17
PL2938740T3 (pl) 2022-07-11
EP2938740A1 (en) 2015-11-04
KR102607543B1 (ko) 2023-11-30
AU2013370404A1 (en) 2015-07-09
IL239565B (en) 2022-05-01
EP2938740A4 (en) 2016-11-30
RU2015130347A (ru) 2017-01-31
CA2895517C (en) 2022-10-11
KR20210100204A (ko) 2021-08-13
US20180177846A1 (en) 2018-06-28
US9925242B2 (en) 2018-03-27
SG10202100667SA (en) 2021-02-25
ZA201504484B (en) 2017-11-29
AU2013370404B2 (en) 2017-11-02
BR112015014897A2 (pt) 2018-05-22
CN108888757A (zh) 2018-11-27
MX2015008226A (es) 2015-12-08
NZ630469A (en) 2017-02-24
CN105008548B (zh) 2020-11-27
SG11201504815QA (en) 2015-07-30
ES2915851T3 (es) 2022-06-27
US20230226151A1 (en) 2023-07-20
WO2014105939A1 (en) 2014-07-03
CN105008548A (zh) 2015-10-28
KR20230164238A (ko) 2023-12-01
IL292303A (en) 2022-06-01
RU2675514C2 (ru) 2018-12-19
JP2016513073A (ja) 2016-05-12
US20190175694A1 (en) 2019-06-13
US20190175692A1 (en) 2019-06-13
US20160045565A1 (en) 2016-02-18
US11564972B2 (en) 2023-01-31
US20190175693A1 (en) 2019-06-13
EP2938740B1 (en) 2022-04-20
KR20150104579A (ko) 2015-09-15
CA2895517A1 (en) 2014-07-03
DK2938740T3 (da) 2022-06-20
IL239565A0 (en) 2015-08-31
EP4083221A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
MX2021006856A (es) Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares.
MX349869B (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas.
WO2014085365A3 (en) Compositions and methods for treatment of metabolic disorders and diseases
WO2015195509A3 (en) Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2015183890A3 (en) Methods and compositions for the treatment of metabolic disorders and diseases
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
MX2013005639A (es) Metodos para el tratamiento de transtornos asociados con fgf21.
TN2014000110A1 (en) Dual function proteins for treating metabolic disorders
MX336391B (es) Metodos y composiciones que usan polipeptidos de fusion de fgf23.
MX2016005101A (es) Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso.
MX2018009524A (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.
NZ628625A (en) Polypeptides binding to human complement c5
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
MX2010005280A (es) Nuevos peptidos sinteticos sustituidos con arginina y su uso.
NZ738982A (en) Composition comprising amino acid and cyclic dipeptide
TN2013000211A1 (en) Methods of treating fgf 21- associated disorders